Siemens combo tests for SARS-CoV-2, flu, RSV
October 2022—Siemens Healthineers released its CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay and Clinitest Rapid COVID-19 plus Influenza Antigen Test.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Mdxhealth buys Oncotype DX GPS business
October 2022—Mdxhealth has entered into a purchase agreement with Genomic Health, a subsidiary of Exact Sciences, to acquire Exact Sciences’ Oncotype DX Genomic Prostate Score test and most of the company’s team of urology sales and marketing professionals.
Hamilton, Bionano announce UHMW DNA extraction solution
September 2022—Hamilton and Bionano Genomics announced the development of the Long String Vantage for isolating ultra high molecular weight DNA for use in optical genome mapping. The Bionano Prep SP Blood and Cell Culture DNA Isolation Kit runs on the Long String Vantage and can obtain up to 12 UHMW DNA samples in less than four hours.
BD COVID-19, flu A/B, RSV test gets CE mark
September 2022—BD announced that the BD Max Respiratory Viral Panel, a molecular diagnostic combination test for SARS-CoV-2, influenza A and B, and respiratory syncytial virus, has been CE marked to the IVD directive 98/79/EC. The test uses a single nasal swab or a single nasopharyngeal swab sample to determine if a patient has COVID-19, flu, or RSV.
BD, Accelerate announce collaboration for antimicrobial ID Dx
September 2022—BD and Accelerate Diagnostics announced a worldwide commercial collaboration agreement in which BD will offer Accelerate’s rapid testing solution for antibiotic resistance and susceptibility. Under the agreement, BD will market and sell the Accelerate Pheno system and Accelerate Arc module and associated test kits through its worldwide sales network in territories where products have regulatory approval or registration.
Verichem clinical reference materials for microprotein, CO2 testing
September 2022—Liquid-stable and ready-to-use clinical reference materials for microprotein testing are available from Verichem Laboratories. The products are intended for the calibration and calibration verification of clinical systems testing for total protein and albumin in urine and cerebrospinal fluid samples and incorporate human protein components for optimum reactivity.
Bio-Rad launches RNA library prep kit
September 2022—Bio-Rad Laboratories has launched its SEQuoia Express Stranded RNA Library Prep Kit. The three-tube kit uses a novel reverse transcriptase with ligation-free adapter addition chemistry to yield a reproducible, quantitative RNA sequencing library in three hours. The kit enables users to construct robust libraries that capture mRNA and long noncoding RNA (>200 bp) transcripts for differential gene expression analysis and novel transcript discovery.
Roche receives EUA for Cobas SARS-CoV-2 Duo
September 2022—Roche announced that the FDA issued emergency use authorization for the Cobas SARS-CoV-2 Duo for use on the fully automated Cobas 6800/8800 systems. The real-time RT-PCR assay is for the in vitro qualitative and quantitative detection of SARS-CoV-2 RNA in nasal and nasopharyngeal swab specimens. The assay also performs quantitation of SARS-CoV-2 RNA levels in the collected specimen; however, only the qualitative result of the assay is intended for use as an aid in diagnosing SARS-CoV-2 infection in patients suspected of COVID-19 by their health care provider.
Study shows Abbott’s TBI test could predict outcomes from brain injury
September 2022—Abbott announced that a study published in Lancet Neurology demonstrates the ability of two blood-based biomarkers to predict how a person will recover from traumatic brain injury (TBI) (Korley FK, et al. Lancet Neurol. 2022;21[9]:803–813).
Roche COVID-19 test detects, differentiates BA.2.75
September 2022—Roche and its subsidiary TIB Molbiol have developed a COVID-19 test that detects and differentiates the BA.2.75 subvariant. The VirSNiP SARS-CoV-2 Spike 147E 152R test, for research use only, targets two of the known unique mutations, K147E and W152R, in BA.2.75, which allows clear differentiation against other notable subvariants. The test is for use on the Lightcycler and Cobas z480 instruments and is available worldwide.